RxDoctor Payments Data

Katherine Janaszek

Family · Stanford, CANPI 1306383286

Payments from drug & device makers

$4,101in general payments, 2019–2025

Across 81 payments — averaging $50.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Novartis$449
  • Boston Scientific$384
  • E.r. Squibb & Sons, L.L.C.$191
  • Novo Nordisk$178
  • Medtronic$152
  • plus $654 from 12 others

What the payments were for

  • Consulting fees$2,00049%
  • Food & beverage$2,10151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,101 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$19,321
Medicare patients
166
Services billed
408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$29,226
JardianceEmpagliflozin17$27,611
EntrestoSacubitril/Valsartan21$20,068
Ranolazine ErRanolazine11$1,886
Rosuvastatin Calcium107$1,586
Ezetimibe39$1,140
ClopidogrelClopidogrel Bisulfate37$759
Metoprolol Succinate44$751
Losartan Potassium59$715
Atorvastatin Calcium60$683
Nifedipine ErNifedipine12$334
Carvedilol21$306
Amlodipine Besylate31$175
Lisinopril20$155
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide11$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$29,22623 claims
Boehringer IngelheimJardiance$30$27,61117 claims
NovartisEntresto$449$20,06821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →